LUGANO, Svizzera–(BUSINESS WIRE)–Lo Switzerland Eye Research Institute ha annunciato che, secondo quanto riportato da un comunicato stampa, la rivoluzionaria formulazione a base di ribloflavina transepiteliale nota come ParaCel, frutto della ricerca dell’amministratore delegato e fondatore dell’istituto, il Dr. Roberto Pinelli, è stata scelta dalla FDA insieme a diverse altre per un protocollo di cross-linking del collagene corneale epi-on (senza asportazione dell’epitelio corneale) per i paz
Author: Business Wire
SERI Lugano: ParaCel riboflavine geselecteerd door FDA voor epi-on crosslinking voor keratoconus
LUGANO, Zwitserland–(BUSINESS WIRE)–Het Switzerland Eye Research Institute heeft aangekondigd dat de doorbraakformulering voor transepitheliale riboflavine, bekend als ParaCel, en op basis van het onderzoek van haar CEO en oprichter Roberto Pinelli, MD, door de FDA uit vele inzendingen is geselecteerd voor een behandelprotocol voor epithelial-on corneale collageen crosslinking voor patiënten met progressieve keratoconus, volgens een persbericht. Alle intellectuele eigendomsrechten voor het pr
SERI Lugano : La riboflavine ParaCel est sélectionnée par la FDA pour être utilisée dans le cadre du crosslinking epi-on pour le kératocône
LUGANO, Suisse–(BUSINESS WIRE)–Le Switzerland Eye Research Institute a annoncé que la formulation de riboflavine transépithéliale novatrice, connue sous le nom de ParaCel et basée sur la recherche de son président-directeur général et fondateur Roberto Pinelli, MD, avait été sélectionnée parmi un grand nombre d’autres formulations par la FDA (Food and Drug Administration – Agence américaine de contrôle des produits alimentaires et médicamenteux) pour un protocole de crosslinking (CXL) (réticu
Global $58.44 Billion Ophthalmic Equipment Market Forecasts by Product, 2018-2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Equipment Market by Product – Global Forecasts to 2023” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic equipment market is expected to reach USD 58.44 billion by 2023 from USD 49.30 b…
Omeros Announces Amendment of Credit Facility
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm. With respect to the twelve-month period beginning on January 1, 2018, the amendment deems Omeros to have met the financial covenants requiring the company to achieve a minimum net revenue or market capitalization amount. The net revenue and market capitalization covenants will co
SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconus
LUGANO, Switzerland–(BUSINESS WIRE)–ParaCel riboflavin invented by Dr. Roberto Pinelli, released to AVEDRO in 2011, has been chosen among others by the FDA for a new epi-on crosslinking.
LENSAR® Laser System Receives FDA Clearance to Perform Corneal Pockets and Flaps for Corneal Inlay Procedures
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR receives FDA clearance for LENSAR Laser System with Streamline IV to perform corneal pockets and flaps for corneal inlay procedures.
Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Global Optometry/Eye Exam Equipment Market by Type, End User – Forecast to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optometry/Eye Exam Equipment Market by Type, End User – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. “The eye exam equipment market is projected to grow at a CAGR of 6.0% between 201…
The Global Ophthalmic Surgical Instruments Market is Estimated to Reach USD 11.18 Billion by 2022 from USD 8.36 Billion in 2017, at a CAGR of 6.0% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Surgical Instruments Market – Global Forecast to 2022” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic surgical instruments market is expected to reach USD 11.18 billion by 2022…
Top Student Inventors Awarded Lemelson-MIT Student Prize
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#InvenTeams–Following a nationwide search for the most inventive college students, the Lemelson-MIT Program today announced the winners of the 2018 Lemelson-MIT Student Prize. The Program awarded a total of $80,000 i…
Hemovent Starts GLP in vivo Trial for Long-Term Use of Its Next-Gen ExtraCorporeal Membrane Oxygenation (ECMO) System
AACHEN, Germany–(BUSINESS WIRE)–Hemovent GmbH announced today that it has commenced a GLP in vivo study for the long-term (7 days) use of its novel and portable artificial lung technology platform, designed for a wide range of indications from ExtraC…
Avedro Names James Schuermann Chief Business Officer
WALTHAM, Mass.–(BUSINESS WIRE)–#crosslinking–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that James F. Schuermann has joined the company as Chief Business Officer (CBO). Mr. Schuermann will lead the global government affairs, health economics and reimbursement, communications, sales, field service, marketing and business development functions and will report to Avedro’s Chief Executive Officer, Reza Zadno. “Jim joins us a
Swiss Advanced Visionが白内障向けにリアルタイムのオートフォーカス機能を搭載した能動眼内レンズ構想を発表
スイス・ヌーシャテル–(BUSINESS WIRE)–（ビジネスワイヤ）– Swiss Advanced Vision（SAV-IOL）は、世界の眼内レンズ（IOL）市場を根底から変革することになるR-TASCプロジェクトの発足について発表しました。 白内障は世界の失明症例のうち51%の原因となっており、失明者は約3500万人に上ります。世界市場が拡大している眼内レンズは2017年の推計35億米ドルから2022年までに45億6000万米ドルに達すると見込まれており、年平均成長率（CAGR）は5.4%となります。この市場成長を促進しているのが、人口高齢化、世界における眼疾患および糖尿病の増加、白内障による失明を管理・治療するための政府イニシアチブです。 ただ、市場規模の大きさにもかかわらず、眼内レンズには目立った革新成果が生まれてきませんでした。SAV-IOLは眼内レンズに取り組むためのまったく新しい手法を開発しています。R-TASC（Real-Time Autofocus Servo Control、リアルタイム・オートフォーカス・サーボ・コントロール）は、リアルタイムのオート
Swiss Advanced Vision上市用於白內障手術的即時自動對焦主動式人工水晶體概念
瑞士紐沙提勒–(BUSINESS WIRE)–(美國商業資訊) — Swiss Advanced Vision (SAV-IOL)宣布啟動R-TASC計畫，以此攪局全球人工晶體(IOL)市場。 全球失明者中有51%（約3500萬人）為白內障所致。IOL是成長中的全球性市場，預計市場規模將從2017年的35億美元增至2022年的45.6億美元，年複合成長率達5.4%。驅動該市場成長的是人口高齡化、全球眼疾和糖尿病發病率的攀升，以及政府在控制和治療白內障所致失明方面的措施。 然而，儘管有此市場規模，IOL領域值得關注的創新卻寥寥無幾。SAV-IOL正在針對IOL制定一種全新的方法。R-TASC（Real-Time Autofocus Servo Control，即時自動對焦伺服控制）是一種即時自動對焦和無線互聯的主動式水晶體。現有的所有水晶體均為定焦，視光學效果會有所犧牲，例如配光曲線、解析度和視覺干擾。這是其靜態設計的固有弊病，無法克服白內障手術後的（視力）調節功能失調問題。 R-TASC旨在徹底恢復眼精水晶體正常情況下所提供的調節功能。R-TASC水晶體採用一個能量擷取系統，能
Swiss Advanced Vision上市用于白内障手术的实时自动对焦主动式人工晶体概念
瑞士纳沙泰尔–(BUSINESS WIRE)–(美国商业资讯) — Swiss Advanced Vision (SAV-IOL)宣布启动R-TASC项目，以此搅局全球人工晶体(IOL)市场。 全球失明者中有51%（约3500万人）为白内障所致。IOL是增长中的全球性市场，预计市场规模将从2017年的35亿美元增至2022年的45.6亿美元，复合年均增长率达5.4%。驱动该市场增长的是人口老龄化、全球眼疾和糖尿病发病率的攀升，以及政府在控制和治疗白内障所致失明方面的举措。 然而，尽管有此市场规模，IOL领域值得关注的创新却寥寥无几。SAV-IOL正在针对IOL制定一种全新的方法。R-TASC（Real-Time Autofocus Servo Control，实时自动对焦伺服控制）是一种实时自动对焦和无线互联的主动式晶状体。现有的所有晶状体均为定焦，视光学效果会有所牺牲，例如配光曲线、分辨率和视觉干扰。这是其静态设计的固有弊病，无法克服白内障手术后的（视力）调节功能失调问题。 R-TASC旨在彻底恢复眼晶状体正常情况下所提供的调节功能。R-TASC晶状体基于一个能量捕捉系统，能
Swiss Advanced Vision presenta el concepto de lente intraocular activa con enfoque automático en tiempo real para la cirugía de cataratas
NEUCHATEL, Suiza–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha anunciado el lanzamiento del Proyecto R-TASC, destinado a transformar el mercado global de las lentes intraoculares (LIO). Las cataratas son responsables del 51 % de los casos de ceguera del mundo, lo que representa unos 35 millones de personas. El mercado global de las LIO está en pleno crecimiento, está previsto que alcance los 4560 millones de dólares en 2022, desde los aproximadamente 3500 millones de dólares en 2017, a u
Swiss Advanced Vision lança conceito de lente intraocular com autofoco em tempo real para cirurgia de catarata
NEUCHATEL, Suíça–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) anunciou o lançamento do Projeto R-TASC, criado para revolucionar o mercado global de lentes intraoculares (LIO). A catarata é responsável por 51% dos casos de cegueira no mundo, o que representa cerca de 35 milhões de pessoas. As LIOS, que constituem um mercado global crescente, alcançaram 4,56 bilhões de dólares em 2022, com um crescimento anual de 5,4% em relação aos 3,50 bilhões de dólares de 2017. O que impulsiona o crescim
Riassunto: Swiss Advanced Vision lancia un concetto di lente intraoculare attiva autofocalizzante in tempo reale per intervento di cataratta
NEUCHATEL, Svizzera–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) ha annunciato il lancio di Project R-TASC, che rivoluzionerà il mercato globale delle lenti intraoculari (IOL). La cataratta è responsabile del 51% dei casi di cecità nel mondo, ovvero circa 35 milioni di persone. Quello delle IOL è un mercato globale in aumento, che si prevede raggiungerà volumi di 4,56 miliardi di dollari USA entro il 2022 da uno stimato 3,50 miliardi nel 2017, ad un tasso di crescita annuale composto (CAGR
Samenvatting: Swiss Advanced Vision lanceert actief intraoculair lensconcept met real-time autofocus voor staaroperaties
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) heeft de lancering van Project R-TASC aankondigd, ingesteld om de global intraocular lens (IOL) markt te verstoren. Staar is wereldwijd gezien verantwoordelijk voor 51% van de bli…